- Home
- CRDF vs ALEC Comparison
CRDF vs ALEC Comparison
Compare CRDF & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ALEC
- Stock Information
- Founded
- CRDF 1999
- ALEC 2013
- Country
- CRDF United States
- ALEC United States
- Employees
- CRDF N/A
- ALEC N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ALEC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRDF Health Care
- ALEC Health Care
- Exchange
- CRDF Nasdaq
- ALEC Nasdaq
- Market Cap
- CRDF 152.3M
- ALEC 124.0M
- IPO Year
- CRDF N/A
- ALEC 2019
- Fundamental
- Price
- CRDF $2.15
- ALEC $1.28
- Analyst Decision
- CRDF Strong Buy
- ALEC Hold
- Analyst Count
- CRDF 4
- ALEC 9
- Target Price
- CRDF $10.63
- ALEC $3.40
- AVG Volume (30 Days)
- CRDF 723.0K
- ALEC 5.5M
- Earning Date
- CRDF 11-06-2025
- ALEC 11-06-2025
- Dividend Yield
- CRDF N/A
- ALEC N/A
- EPS Growth
- CRDF N/A
- ALEC N/A
- EPS
- CRDF N/A
- ALEC N/A
- Revenue
- CRDF $501,000.00
- ALEC $69,048,000.00
- Revenue This Year
- CRDF N/A
- ALEC N/A
- Revenue Next Year
- CRDF N/A
- ALEC $314.69
- P/E Ratio
- CRDF N/A
- ALEC N/A
- Revenue Growth
- CRDF N/A
- ALEC 12.26
- 52 Week Low
- CRDF $1.90
- ALEC $0.87
- 52 Week High
- CRDF $5.64
- ALEC $6.05
- Technical
- Relative Strength Index (RSI)
- CRDF 43.50
- ALEC 31.88
- Support Level
- CRDF $2.06
- ALEC $1.17
- Resistance Level
- CRDF $2.33
- ALEC $1.60
- Average True Range (ATR)
- CRDF 0.11
- ALEC 0.14
- MACD
- CRDF -0.01
- ALEC 0.01
- Stochastic Oscillator
- CRDF 25.00
- ALEC 5.88
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.